natgillin/translations-raw huggingface dataset:
Trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-l-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine for use according to claim 1 or 2, wherein the therapeutically effective amount is divided into one, two, three or four daily doses. 
Trans-4-12-[4-(2,3-diklorofenil)-piperazin-1-il|-etilt-N,N-dimetilkarbamoil-cikloheksilamin za uporabu prema zahtjevu 1 ili 2, naznačen time, da je terapeutski učinkovita količina podijeljena u jednu, dvije, tri ili četiri dnevne doze.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropidin. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) biksafen.
Reflux was maintained for 20 minutes then temperature was allowed to cool to room temperature under stirring for 2 h30. 
Refluks se održava 20 minuta a potom se temperatura spusti na sobnu uz miješanje tijekom 2 sata i 30 min.
A process for producing an expanded, cellular material according to anyone of items 1 to 3, comprising at least 50 wt% of post-consumer PET resin and less than 50 wt% of virgin PET resin, wherein the post-consumer PET resin is carefully cleaned from dust and moisture, compounded and filtered in an extruder and afterwards granulated, and wherein during the subsequent foam extrusion of the granulated material the viscosity of the post-consumer resin is increased by means of a reactive additive (RA) and a physical blowing agent is introduced to the mixture, wherein 
Postupak za proizvodnju ekspandiranog pjenastog materijala prema bilo kojem od patentnih zahtjeva 1 do 4, koji sadrži najmanje 50 g post-potrošačke PET smole na 100 g 1 manje od 50 g djevičanske PET smole na 100 g naznačen time da je post-potrošačka PET smola pažljivo očišćena, složena te se filtrira u ekstruderu i nakon toga granulira, 1 pri čemu se tijekom naknadne ekstruzije pjene iz granuliranog materijala, viskoznosti post-potrošačke smole povećava pomoću lanca koji se produžuje, reaktivni aditiv i fizikalni agens za upuhivanje se dodaje u smjesu.
an effective amount of a composition comprising nanoparticles comprising a taxane and a carrier protein, wherein the taxane is paclitaxel and wherein the carrier protein is albumin, and 
(a) djelotvornu količinu pripravka koji sadrži nanočestice koje sadrže taksan i protein-nosač, gdje je taksan paklitaksel, a gdje je protein-nosač albumin, i
A crystalline form (Form A) according to claim 17 or 18 having a peak at a chemical shift of approximately 134.7 ppm in a 13C solid state NMR spectrum. 
Kristalni oblik (Oblik A) u skladu s patentnim zahtjevom 17 ili 18, naznačen time, da je njegov maksimum u kemijskom pomaku otprilike 134.7 ppm u 13C NMR spektru u krutom stanju.
As a result, the air-tight covering 3 will be sucked into the channel part 7, as can be seen in Fig. 1b and Fig. 1c. 
To ima posljedicu da će se neprodušan pokrov 3 usisati u dio kanala 7, kao što se to može vidjeti na slici Ib i slici 1c.
A composition for use according to claim 1 for increasing an initial period of undisturbed sleep and/or reducing nocturnal voids in a female patient above 50 years of age. 
Pripravak za uporabu prema patentnom zahtjevu 1, naznačen time da je povećanje u početnom periodu nesmetanog spavanja od 37 do 114 minuta, poželjno od 76 do 114 minuta.
The method according to claim 11 wherein said autoimmune disease is selected from the group consisting of rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, ulcerative colitis, and graft-versus-host disease. 
Izolirano protutijelo za uporabu prema zahtjevu 8, naznačeno time da je navedena autoimuna bolest odabrana iz skupine koja se sastoji od reumatoidnog artritisa, sistemskog eritemskog lupusa, upalne bolesti crijeva, ulcerativnog kolitisa i bolesti presatka protiv domaćina.
In preferred embodiments the antisense strand is SEQ ID NO:127 and comprises 2'OMe modified ribonucleotides at positions 3, 5, 9, 11, 13, 15, 17, and 19; a 2'-5'-ribonucleotide in position 7; and a non-nucleotide moiety covalently attached at the 3'-terminus; and the sense strand is SEQ ID NO:60 and comprises five consecutive 2'-5'-ribonucleotides in the 3'-terminal positions 15, 16, 17, 18, and 19; a non-nucleotide moiety covalently attached at the 3'-terminus; and an inverted abasic moiety covalently attached at the 5'-terminus. In some embodiments the double-stranded nucleic acid molecule further includes a 2'OMe modified ribonucleotide or a 2'-5'-ribonucleotide at position 1 of the antisense strand. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačen time što protusmisleni lanac sadrži SEQ ID NO:127, a smisleni lanac sadrži SEQ ID NO:60; gdje protusmisleni lanac dodatno sadrži 2'-O- metilom modificirane ribonukleotide na položajima 3, 5, 9, 11, 13, 15, 17, te 19; 2'-5'-ribonukleotid na položaju 7; i nenukleotidni ostatak kovalentno vezan na 3'-kraju; te gdje smisleni lanac dodatno sadrži pet uzastopnih 2'-5'- ribonukleotida na 3'-terminalnim položajima 15, 16, 17, 18, te 19; nenukleotidni ostatak kovalentno vezan na 3'- kraju; i invertirani nebazni ostatak kovalentno vezan na 5'-kraju.
first and second nuts (56, 58) each threadably engaging a separate one of said oppositely threaded portions of said ball screw, said nuts being reciprocatable toward and away from each other along said ball screw upon rotation of said ball screw, 
- prvu i drugu maticu (56), (58), od kojih svaka zahvaća po jedan od spomenutih suprotnih navoja, a spomenute matice se pomiču jedna prema drugoj i jedna od druge po spomenutom kuglastom vijku, zbog okretanja spomenutog vijka,
The method of claim 10, wherein the energy is electricity, or wherein the energy is steam, or wherein the fossil fuel is coal, optionally wherein the coal is lignite, sub-bituminous coal, bituminous coal, anthracite coal, or combinations thereof. 
Postupak u skladu s patentnim zahtjevom 10, naznačen time, da je energija električna energija ili energija je vodena para ili fosilno gorivo je ugljen, po izboru ugljen je lignit, sub-bitumenski ugljen, bitumenski ugljen, antracitni ugljen ili njihove kombinacije,
Max. and min. transmission 
Max. i min. transmisije
the distribution of molecular weights of the polysaccharides in the chemically modified glycosaminoglycan are expressed as cumulative % of weight according to the following table: Molecular 
(vi) kemijski modificirani glukozamonoglikani imaju raspored polisaharida 1 njihove odgovarajuće molekularne mase izražene kao kumulativni % mase prema tablici:
Process according to any one of the preceding claims, characterized in that the veneer (14) that is obtained in step (iv) has a surface area preferably of from 1 to 4 m2, more preferred of from 1.5 to 3.5 m2. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, što furnir koji se dobije u fazi (iv) ima veličinu površine poželjno od 1 do 4 m", još poželjnije od 1.5 do 3.5 m".
exist in a metastable crystalline phase (see the following), and thereby constitute the filler ingredient. 
mogu postojati u obliku metastabilne kristalne faze (vidi dalje) i stoga sačinjavati sastojak za punilo.
G A kit comprising a live attenuated VZV or whole inactivated VZV and, separately, a VZV antigen or immunogenic derivative therof, the components suitable for concomitant or sequential delivery, or for mixing as a single composition prior to delivery. 
Komplet, naznačen time što sadrži živi oslabljeni VZV i, odvojeno, VZV antigen gE, skraćen kako bi se uklonilo C-terminalno sidrišno područje, u kombinaciji s adjuvansom koji sadrži 3D-MPL, QS21 i liposomima koji sadrže kolesterol, gdje su te komponente pogodne za istodobni ili uzastopni unos, ili za miješanje u jedinstveni pripravak prije unosa.
a buffer for use with the competitive binding assay further comprising an inhibitor of proteinase K. 
(v) pufer namijenjen upotrebi u ispitivanju s kompetitivnim vezanjem, koji dodatno sadrži inhibitor proteinaze K.
or a pharmaceutically acceptable acid addition salt thereof, or a solvate thereof. 
ili njegova farmaceutski prihvatljiva kisela adicijska sol ili njegov solvat.
wherein said first protecting group can be removed from said 3'-amino group under conditions which do not deprotect said nucleoside base, and said second protecting group can be removed from said 5'-hydroxyl group under conditions which do not deprotect said nucleoside base or said 3'-amino group. 
pri čemu navedena prva zaštitna skupina može biti odstranjena iz navedene ’-amino-skupine, pod takvim uvjetima u kojima se neće poništiti zaštita navedene nukleozidne baze, i spomenuta druga zaštitna skupina može biti odstranjena iz spomenute 5’-hidroksil-skupine, pod takvim uvjetima u kojima se neće poništiti zaštita spomenute nukleozidne baze ili spomenute 3’-amino-skupine.
no. name and/or structure 
naziv i/ili struktura "Al"
The system of claim 11, wherein the game is roulette and wherein the one or more interface devices provide a selector for selecting the color of chips, wherein bets of each respective user are displayed as chips having unique color to distinguish their bets from those performed by other users. 
Sustav prema patentnom zahtjevu 7, naznačen time što uređaj (20) za sučelje osigurava birač za izbor boje čipova, kojima ulozi trebaju biti prikazani na stolu za igru, pri čemu su ulozi svakog dotičnog korisnika prikazani kao čipovi koji imaju jedinstvenu boju kako bi se razlikovali njihovi ulozi od onih koje su položili drugi korisnici.
According to certain embodiments, the implantable depot is suitable for subcutaneous or intramuscular implantation. 
Farmaceutski pripravak prema zahtjevu 1 ili 2, pogodan za subkutanu ili intramuskularnu implantaciju.
A prestretched film according to claim 4, having a content of LLDPE in the range of 60-99.9 % by weight and a content of LDPE in the range of 0.1-20 % by weight. 
Prethodno rastegnuta folija prema zahtjevu 3, ima sadržaj LLDPE-a u rasponu od 60-99.9% težine i sadržaj LDPE-a u rasponu od 0.1-20% težine.
The container assembly according to claim 1, wherein the separator is a contrast colour compared to a colour of the tissue. 
Sklop posude prema bilo kojem od prethodnih Zahtjeva, gdje je separator (31) kontrastne boje, poput plave, u odnosu na boju tkiva.
a T cell receptor comprising: a T cell receptor a-chain comprising at least one, preferably two, more preferably all three of the CDR sequences of the T cell receptor a-chain of SEQ ID NO: x or a variant thereof, and 
(D) T staničnog receptora koji sadrži: (i) o-lanac T staničnog receptora koji sadrži sve tri CDR sekvence a-lanca T staničnog receptora od SEK ID BR: x,1
Compounds of formula (I) wherein 
Spojevi formule (I) [image] naznačeni time, da
The resulting linker is a carbonyl group. 
Nastali veznik je karbonilna grupa.
According to another aspect of the invention, the disclosed compounds and compositions are useful for the amelioration of symptoms associated with, the treatment of, and preventing and/or inhibiting the progression of, the following conditions and diseases: periodontal disease, chronic inflammatory airway disease, chronic bronchitis, and chronic obstructive pulmonary disease. 
Spoj za uporabu kako je zatraženo u zahtjevu 19, naznačen time da je bolcst, poremećaj ili stanje odabrano iz skupine koja se sastoji od periodontalne bolesti, kronične upalne bolesti dišnih puteva, kroničnog bronhitisa, te kronične opstruktivne plućne bolesti. Spoj za uporabu kako je zatraženo u zahtjevu 19, naznačen time da bolest, poremećaj ili stanje je rak dojke.
The use of SNRI's have been shown in clinical studies to have a beneficial effect on pain (e.g. Fibromyalgia syndrome, overall pain, back pain, shoulder pain, headache, pain while awake and during daily activities) and especially pain associated with depression (Berk, M. Expert Rev. Neurotherapeutics 2003, 3, 47-451; Fishbain, D. A., et al. 
Kliničke studije pokazale su da korištenje SNRIs ima pozitivan učinak na bol)npr. Fibromvalgia sindrom, opća bol, bol u ledima, bol u ramenu, glavobolja, bol u budnom stanju I tijekom dnevnih aktivnosti) a pogotovo na bol koja je u svezi s depresijom (Berk, m.
The rodent of claim 1, wherein the unrearranged TCRa variable gene locus comprises a complete repertoire of human Ja segments and a complete repertoire of human Va segments and/or the unrearranged TCRB variable gene locus comprises a complete repertoire of human JB segments, a complete repertoire of human DB segments, and a complete repertoire of human VB segments. 
Glodavac prema zahtjevu 1, naznačen time, da nerearanžirani varijabilni TCRa-genlokus obuhvaća cjelokupni repertoar ljudskih Ja-segmenata i cjelokupni repertoar ljudskih Va-segmenata i/ili nearanžirani varijabilni TCRB-genlokus obuhvaća cjelokupni repertoar ljudskih JB-segmenata, cjelokupni repertoar ljudskih DB-segmenata i cjelokupni repertoar ljudskih VB-segmenata.
Preferably, the formulations of the present invention will have an SPF greater than at least about 30, preferably greater than at least about 40, and preferably about 50. 
Poželjno, pripravci iz ovog izuma će imati SPF veći od najmanje oko 30, poželjno veći od najmanje oko 40, 1 poželjno oko 50.
Thus the compounds are useful in the treatment or prevention of a variety of cardiac conditions, such as angina pectoris, cardiac arrythmias, heart attacks and cardiac hypertrophy. 
Tako su spojevi korisni u tretiranju ili prevenciji kardijalnih stanja, kao što je angina pectoris, kardijalne aritmije, srčani napadi i kardijalna hipertrofija.
It is made from the same material as the capsule, preferably plastics. 
Načinjen je od istog materijala kao i čahura, poželjno od plastike.
The B7-H3 binding molecule of claim 7, wherein said Fc modification comprises substitutions of: 
Molekula koja se veže na B7-H3 u skladu s patentnim zahtjevom 7, naznačena time što navedena modifikacija Fc sadrži zamjene:
granulating the materials from the step (3) using a dry granulation process, wherein the dry granulation process comprises: 
granulacije materijala iz koraka (2) korištenjem postupka suhe granulacije koji obuhvaća:
Where necessary, the term "about" can be omitted. 
Gdje je to potrebno, izraz "oko" se može izostaviti.
The volume fraction of monoclinic zirconia Vm can be determined from the following relationships: 
Volumna frakcija monoklinskog cirkonijevog oksida V,, se može odrediti prema sljedećim jednadžbama:
wherein A3 is —(CH2)r-Het in which Het is pyrrolidine, benzothiophene or piperidine, which is unsubstituted or substituted independently of one another once, twice or three times by R1, 
(III), gdje A3 je (CH>),-Het, gdje je Het pirolidin, benzotiofen ili piperidin, koji nije supstituiran ili je međusobno neovisno mono-, di- ili trisupstituiran s R1,
The above-stated materials may optionally be blended with further conventional auxiliary substances known to the person skilled in the art, preferably selected from the group consisting of glyceryl monostearate, semi-synthetic triglyceride derivatives, semi-synthetic glycerides, hydrogenated castor oil, glyceryl palmitostearate, glyceryl behenate, polyvinylpyrrolidone, gelatine, magnesium stearate, stearic acid, sodium stearate, talcum, sodium benzoate, boric acid and colloidal silica, fatty acids, substituted triglycerides, glycerides, polyoxyalkylene glycols and the derivatives thereof. 
Po potrebi se mogu prethodno navedeni materijali pomiješati s daljnjim pomoćnim tvarima poznatim stručnjaku, prvenstveno izabranim iz skupine koja obuhvaća omekšivače, maziva sredstva, antioksidanse, kao na pr. glicerinmonostearat, polusintetske derivate triglicerida, polusintetske gliceride, hidrirano ricinusovo ulje, glicerinpalmitostearat, glicerinbehenat, polivinilpirolidon, želatinu, magnezijev stearat, stearinsku kiselinu, natrijev stearat, talk, natrijev benzoat, bornu kiselinu i koloidni silicijev dioksid, masne kiseline, supstituirane trigliceride, gliceride, polioksialkilenglikole, polialkilenglikole i njihove derivate.
• applying a liquid resin (5), preferably a melamine formaldehyde resin, on the core (3); and 
* nanošenja tekuće smole (5), poželjno melamin formaldehid smole, na jezgru (3); i
The aqueous pharmaceutical suspension according to claim 3, wherein the wetting agent is Poloxamer 407. 
. Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što sredstvo za vlaženje je
a nitro group; R<3> is selected from the group consisting of: 
(8) skupina nitro; R> se bira iz skupine koju čine:
Identity document according to Claim 2, comprising two thread directions at an angle of 90°. Identity document according to Claim 2 or 3, comprising two thread directions at an angle of approximately 60°. 
Osobna isprava u skladu s patentnim zahtjevom 2 ili 3, naznačena time što sadržava dva smjera vlakana, koji smjerovi vlakana su pod kutom od približno 60%.
A method for producing a recombinant Von Willebrand Factor (rVWF) composition, the method comprising the steps of: 
Postupak dobivanja pripravka rekombinantnog Von Willebrandovog Čimbenika (rVWF), naznačen time što se postupak sastoji u koracima:
The latter may comprise an inspection by means of, for example, a TV camera, a cleaning operation by means of a spraying device and the like. 
(54) Naziv izuma: UREĐAJ U OBLIKU KUTIJE NAMIJENJEN DA BUDE SPREMNIK ZA VODU, NA PRIMJER SPREMNIK ZA KISNICU, | POSTUPAK ZA NJEGOVO KORIÅ TENJE
R1i is a hydrogen atom, a lower alkyl group or a halo-lower alkyl group, provided that the compounds wherein R10 is a methyl group and R20 is an unsubstituted phenyl group are excluded. 
uz uvjet da su isključeni spojevi gdje je R10 metil skupina i R20 je nesupstituirana fenil skupina. Spoj općenite formule (I-2) prema zahtjevu 1, ili njegova sol ili ester:
A pressurized metered dose inhaler comprising a canister filled with the pharmaceutical aerosol formulation of any one of the claims 1 to 16, and a metering valve for delivering therapeutically effective doses of the active ingredients. 
Inhalator sa stlačenim inhalatom koji sadrži spremnik napunjen farmaceutskom aerosolnom formulacijom iz bilo kojeg od patentnih zahtjeva 1 do 14, te odmjerni ventil za isporuku terapijski učinkovitih doza aktivnih sastojaka.
Further, as noted above, Set B is the two dimensional library that consists of all permutations of all of the variants of R1 represented in Set A and a set of R2 variants listed above with R3 fixed as 2-(trifluoromethyl)pyridin-5-yhnethyl. 
Dalje, kao što je gore navedeno, Skupina B je dvodimenzionalna kolekcija koja se sastoji od svih permutacija od svih varijacija R' koje su prikazane u Skupini A i skupine R* varijacija koje su gore navedene sa R> koji je fiksiran kao 2-(trifluorometil)piridin-5-ilmetil.
The polypeptide of claim 1, wherein at least one CTP comprises the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2. 
Polipeptid prema zahtjevu 1, naznačen time da sekvenca barem jedne CTP sadrži sekvencu amino kiseline odabranu iz SEQ ID NO: 1 i SEQ ID NO: 2.
A method for applying Zinc-Aluminium pseudo alloy for the outside of underground ductile cast iron piping members as claimed in claim 16, wherein the said pseudo alloy comprises of Zn-60-90%, Al-10-40%, and at least one of the following alloying elements such as Cu-0.2-8%, Mg-0.2-5%, Si-0.1-3, Sr-0.02-0.05. 
Postupak izrade podzemnog elementa cjevovoda od duktilnog lijevanog željeza s premazom od pseudo legure cinka i aluminija prema patentnom zahtjevu 13, naznačen time što navedena pseudo legura sadrži Zn 60-90 mas.%, Al 10-40 mas.%, i najmanje jedan od sljedećih legirajućih elemenata Cu 0.2-8 mas.%, Mg 0.2-5 mas.%, Si 0.1-3 mas.%, Sr 0.02-0.05 mas.%.
A cryogenic tank arrangement according to claim 4, characterized in that the branch conduits (32',32") are arranged outside the tank and arranged to gradually approaching the face of the tank when running from the branch point (30) to the connection point (24',24"). 
Kriogeni spremnik prema zahtjevu 4, naznačen time da su vodovi grananja (32',32") smješteni izvan spremnika i postavljeni da se postupno približavaju prednjoj strani spremnika kada se protežu od točke grananja (30) do spojne točke (24',24").
Summary of the Invention According to a first aspect, the present invention is directed to an article comprising a paper product comprising a co-processed microfibrillated cellulose and inorganic particulate material composition and one or more functional coatings on the paper product. 
Artikl, naznačen time što sadrži: a. = papirni proizvod, koji sadrži suobrađenu mješavinu mikrofibrilirane celuloze 1 anorganskog partikuliranog materijala; i b. jednu ili više funkcionalnih obloga na papirnom proizvodu; gdje mikrofibrilirana celuloza ima močivost vlakana od 20 do 50.
A compound according to claim 1 wherein R1 is chloro, trifluoromethyl or cyano; is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, cyano, C1-4alkyl, C1-4alkyloxy, C1-4alkylsulfonyl, perfluoroC1-4alkyl, perfluoroC1-4alkyloxy, diC1-4alkylamino, hydroxyl, and phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, C1-4alkyl and perfluoroC1-4alkyl; thienyl; thienyl substituted with 1 or 2 substituents each independently selected from the group consisting of halo and C1-4alkyl; naphthyl; pyridinyl; pyrrolyl; benzothiazolyl; indolyl; quinolinyl; C3-8cycloalkyl; or C5-7cycloalkenyl; 
R' je kloro, trifluorometil ili cijano; R je fenil; fenil supstituiran sa 1, 2 ili 3 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo, cijano, Cisalkil, Ciaalkiloksi, Ciaalkilsulfonil, perfluoroC,ualkil, perfluoroC,alkiloksi, diC,valkilamino, hidroksil, 1 fenil supstituiran sa 1, 2 ili 3 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo, Ciaalkil 1 perfluoroC,aalkil; tienil; tienil supstituiran sa 1 ili 2 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo 1 C,aalkil; naftil; piridinil; pirolil; benzotiazolil; indolil; kinolinil; Cagcikloalkil; ili Csgcikloalkenil;
The use according to claim 13, wherein the shaped article is used 
Uporaba prema patentnom zahtjevu 13, pri čemu se oblikovani članak (100) koristi
r and s are independently an integer comprised between 1 and 3; with q+r+s≧4; in the presence of a Fe(acac)3 in an aprotic solvent at a temperature ranging from 0° C. to room temperature. 
Tis su neovisno cijeli brojevi, koji se kreću između 1 i3; gdjeq+r1+s 24; u prisutnosti Fe(acac); u neprotonskom otapalu, poput THF ili NMP, na rasponu temperatura od 0 *C do sobne temperature.
The TCR or functional variant of claim 1 or 3 or the isolated or purified TCR of claim 2 or 3, comprising the amino acid sequences of: (I) 
TCR ili funkcionalna varijanta u skladu s patentnim zahtjevom 1 ili 3 ili izolirani ili pročišćeni TCR u skladu s patentnim zahtjevom 2 ili 3, naznačen time što ima aminokiselinske sljedove:
is halogen, 1-4C-alkyl or 1-4C-alkoxy, or R6 and R7 together form a 1-2C-alkylenedioxy group, or a stereoisomer of the compound. 
R6 i R7 zajedno tvore 1-2C-alkilendioksi-skupinu, ili stereoizomer od toga spoja. Spoj formule 1 prema zahtjevu 1, naznačen time, da
The compound as claimed in claim 5, wherein X is a 5-membered heteroaryl ring having the following structure: wherein each of U, V and W is selected from the group consisting of C, N, O and S, with the proviso that at least one of U, V and W is other than C; prefeably wherein X is selected from the group of thiophene, pyrazole, isoxazole, and oxadiazole groups; more preferably wherein X is thiophene. 
HR P20150977 T1 gdje je svaki od U, V i W izabran iz grupe koju čime C, N, O 1 S, uz uvjet da se najmanje jedan od U, V i W razlikuje od C; poželjno gdje je X izabran iz grupe koju čine tiofen, pirazol, izoksazol i oksadiazol grupe; poželjnije gdje X je tiofen.
The isolated IL-23p19 antibody fragment of claim 1, comprising a light chain variable region amino acid sequence of SEQ ID NO:18. 
(1) varijabilnu sekvencu aminokiselina laganog lanca SEQ ID NO: 18 1 varijabilnu sekvencu aminokiselina teškog lanca $EQ ID NO: 13; ili